Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib versus imatinib in Ph+ CML-CP with suboptimal cytogenetic response to imatinib
2005-005047-26Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia (2 arms), sponsored by Novartis. Primary endpoint: Complete cytogenetic response rate at 12 months. Started Aug 2007; status: completed.
02
Drugs
nilotinib
03
Conditions
Philadelphia chromosome-positive chronic myeloid leukemia
Beyond the preview
Go deeper on 2005-005047-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005047-26.